As detailed in The Highwire video (below), in January 2020, Dr. Julie Gerberding (above) — director of the U.S. Centers for Disease Control and Prevention from 2002 until 2009, who after leaving the CDC became president of Merck’s vaccine division in January 20101 — sold half her Merck stock options for $9.11 million.
Gerberding also cashed in on her company stock options in 2016, when she sold $5.1 million-worth of Merck stocks, and 2015, when she made $2.3 million. In total, Gerberding has made $16,592,144 from selling off her Merck stocks — all of which, by the way, is over and beyond her regular paycheck — and she still owns Merck stocks worth $9 million.
And we’re supposed to believe she has been impartial about vaccine safety and has been all along? As noted by Del Bigtree in his Highwire report:
“Do you trust the information that come from your government agencies, when a year after working [at] that agency, they move into the very company that they exonerated from any wrongdoing and end up making $20-something-million dollars in stock options, plus a gigantic salary? Sounds like a payoff to me.”
Quid Pro Quo
The payoff Bigtree is talking about refers back to Gerberding’s exoneration of the MMR vaccine, which came under fire when Dr. William Thompson, a CDC research scientist, blew the whistle claiming the agency covered up a vaccine-autism connection in relation to the MMR vaccine.
According to Thompson, scientific fraud was committed for the express purpose of covering up potential safety problems so the agency would be able to maintain that the MMR vaccine had been proven safe to give to all children.
Thompson explained they simply eliminated the incriminating data, thereby vanishing the link, and this cover-up occurred while Gerberding headed up the CDC. The CDC subsequently also blocked a request for Thompson to testify in an autism lawsuit.
Indeed, you’d have to be really naïve not to see the enormous influence her former high-level ties to the CDC can have, considering Merck makes a majority of the pediatric and adults vaccines recommended by the CDC.
The vaccine industry is booming, and it’s become quite clear that profit potential is the driving factor behind it. One of the reasons for this is because vaccine patents do not expire like drugs do, so each vaccine adopted for widespread use has the potential to make enormous, continuous profits for decades to come.
Vaccine makers also enjoy a high degree of immunity against lawsuits — and in the case of pandemic vaccines, absolute immunity — so the financial liability when something goes wrong is exceptionally low, compared to drugs.